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ABSTRACT
Severe pain has profound physiologic effects on
the endocrine system. Serum hormone
abnormalities may result and these serve as
biomarkers for the presence of severe pain and
the need to replace hormones to achieve pain
control. Initially severe pain causes a
hyperarousal of the hypothalamic–pituitary–
adrenal system which results in elevated serum
hormone levels such as adrenocorticotropin,
cortisol, and pregnenolone. If the severe pain
does not abate, however, the system cannot
maintain its normal hormone production and
serum levels of some hormones may drop below
normal range. Some hormones are so critical to
pain control that a deficiency may enhance
pain and retard healing.
Keywords: Deficiencies; Endocrine system;
Hormone; Hyperarousal; Pain; Replacement
INTRODUCTION
Severe pain has profound physiologic effects on
the endocrine system [1–12]. Fundamentally,
severe pain, whether it be acute or chronic, is a
severe stressor that activates the hypothalamic–
pituitary–adrenal–thyroid–gonadal (HPATG)
system, which is the major stress control
mechanism of the body [10, 13–16]. This
system is often referred to as an ‘axis’ since it
is a closed system with hormonal feedback or
controls within the system [16–18]. This paper
will refer to the ‘axis’ as the HPATG system. The
biologic purpose of this system (see Fig. 1) is to
produce additional hormones in the thyroid,
adrenals and gonads, and secrete them into the
serum as these compounds are required by the
body for many pain-control functions,
including protection and regeneration of
injured tissue, immunologic activity, and
metabolic controls [13, 16, 17]. Once these
extra hormones, such as thyroid, cortisol, or
testosterone, enter the serum, they travel
throughout the body to target areas, including
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injured nerves and the central nervous system
(CNS) [18, 19]. Although it is known that pain
has an effect on neurohormones produced in
the brain, insulin produced in the pancreas, and
adrenalin produced in the adrenal medulla,
there are few studies or reports on these effects
[1–5], and they will not be covered here. Over
the past 50 years, however, there have been
numerous reports and studies on pain’s
physiologic effect on the HPATG system, so
this is the focus of this paper [1–12, 20–30]. It is
also cogent to note that the accumulated
information and understanding about the
effects of pain on the HPATG system is now
such that testing and replacement of certain
hormones should be a basic foundation of
clinical pain treatment.
HORMONE FUNCTIONS IN PAIN
CONTROL
Adequate pain control may not be achieved
without homeostasis of certain hormones
[31–52]. Hormonal homeostasis is defined here
as the maintenance of a hormone within a
normal serum range. The critical pain-control
hormones that are produced in glands
outside the CNS are cortisol, pregnenolone,
dehydroepiandrosterone (DHEA), progesterone,
testosterone, estrogen, and thyroid (Table 1)
[31–52]. Among the primary pain-control
functions of these hormones are immune and
anti-inflammatory actions, cellular protection,
tissue regeneration, glucose control, and
modulation of CNS receptors, the blood–brain
Fig. 1 Pain stimulation of the hormone system causes
adrenal, gonad and thyroid hormone levels to elevate in the
serum. If pain remains uncontrolled for a considerable time
period, hormonal depletion may occur, and serum levels
drop below normal
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barrier, and nerve conduction (Table 2) [53–63].
Given the CNS effects of certain hormones,
analgesics such as anti-depressants, neuropathic
agents and opioids, may not achieve maximal
analgesic responses without hormone
homeostasis [19, 33, 37, 42, 49–53].
The Releasing Hormones
Pain signals that reach the brain from any injury
in the peripheral nervous system activate three
releasing hormones in the hypothalamus (Fig. 1)
[8, 9, 15, 48]. These are corticotropin releasing
hormone (CRH), gonadal releasing hormone
(GRH), and thyroid releasing hormone (TRH) [8,
9, 12, 48]. These three hormones, in turn, cause
the anteriorpituitary to release intoserum adrenal
corticotropin hormone (ACTH), follicle
stimulating hormone (FSH), luteinizing
hormone (LH), and thyroid stimulating
hormone (TSH). The end organs for stimulation
are the adrenals, gonads, and thyroid, which
release into the serum hormones necessary for
pain control including cortisol, pregnenolone,
DHEA, testosterone, progesterone, estrogen,
triiodothyronine (T3), and thyroxine (T4)
(Table 1). Adrenalin and other catecholamines
are also released fromthe adrenal medulla, but it is
only partially a result of ACTH stimulation. Serum
concentrations of the pituitary and end-organ
hormones can now be assayed in commercial
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Table 3 Clinical features of Cushing’s Syndrome and the
proportion of patients affected by these features
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laboratories and replacement hormones are also
readily available. Consequently, the old saying
that pain, ‘‘cannot be measured’’ needs to be
modified. Serum levels of the pituitary and end-
organ hormones noted here serve as biomarkers
for uncontrolled pain (seeTable 3) [3, 7, 30, 64]. In
other words, it may not be possible to quantitate
pain per se, but it is now possible to determine
whether pain severity has reached a level that
activates the HPATG system [29, 64]. It should be
noted that commercial assays for the
hypothalamic-releasing hormones (CRH, GRH,
TRH) are in the developmental stages, and when
available, will provide an even more direct
assessment of brain overstimulation because of
pain [48].
The Stimulation Phase
It is important to note that only severe pain will
stimulate HPATG to the point that the end
organs produce and secrete sufficient hormones
to raise serum levels above normal (Fig. 1) [29,
65]. Studies show that patients with mild or
intermittent pain, such as in common
degenerative arthritis, have normal hormone
serum levels [65]. This is an excellent practical
point for the pain practitioner, since normal
serum hormone levels usually mean that the
patient’s pain is not in need of therapy with
high-risk treatment, such as long-acting opioid
drugs or invasive interventions [66–74]. Put
another way, hormone serum levels are
excellent biomarkers that help separate severe
from mild pain. If end-organ serum hormone
levels are above normal, however, enhanced
pain-control treatment will be needed [75]. If
hormones are below normal levels, it is prudent
to replace the hormones and achieve
homeostasis before embarking on a therapeutic
regimen that has risks, such as opioid-induced
endocrine suppression [23, 66–74].
The Depletion Phase
If tissues in the hypothalamus, pituitary,
adrenals, gonads, or thyroid cannot sustain
the demands of severe pain, serum levels of
some hormones may drop below normal levels
[10, 29, 64]. Based on the clinical experience to
date, the most common end-organ hormones to
diminish in the serum due to uncontrolled pain
are cortisol, pregnenolone, DHEA, and
testosterone [29, 30, 75]. It is noted that
thyroid depletion occurs, but is quite
uncommon according to today’s testing
technology [21]. Also, some clinicians believe
that thyroid depletion should be assessed
according to the symptoms rather than
current assays for T3 and T4 [26]. Once pain is
controlled and/or hormones are replaced,
serum levels will almost always return to
normal. It should be emphasized that only
severe pain will stimulate HPATG to the point
that the end organs will not produce sufficient
hormones to maintain homeostasis [65].
CORTISOL ABNORMALITIES:
THE MOST SERIOUS HORMONE
COMPLICATIONS
Chronic cortisol abnormalities, when levels are
either too high or too low, over an extended time
period are the major hormonal problems in
chronic pain patients. Although the prevalence
of cortisol abnormalities in chronic pain patients
is unknown, excess and deficient cortisol states
are starting to be recognized among pain patients
[7, 10, 29]. Extended periods of exposure to excess
cortisol, often referred to as Cushing’s Syndrome,
named after Harvey Cushing who first described
the clinical signs and symptoms in patients with
pituitary tumors, has serious complications [76–
82]. Complications include osteoporosis,
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hypertension, hyperlipidemia, and mental
deficiencies (Table 3). Until now, many of these
complications in pain patients were simply
viewed as unrelated, random events. Table 3 lists
the complications of hypercortisolemia [84]. The
major complications that manifest in pain
patients are osteoporosis, joint degeneration,
tooth decay, hypertension, hyperlipidemia,
obesity, and mental deterioration [76–82].
Although the hypercortisol complications listed
here are well known, the pain patient may
decondition themselves to adequately move or
exercise. Consequently, multiple reasons for
these complications may develop.
The disease originally described by Cushing
was due to pituitary adenomas, which we now
know is caused by the constant secretion of
ACTH by the pituitary, which raises serum
cortisol levels [76–78, 82]. In chronic pain
patients, hypercortisolemia is usually episodic
and only occurs during flares or periods of
undertreatment that force the hypothalamus
and pituitary to temporarily secrete ACTH and
cortisol. Physiologically, however, it makes
little difference whether high serum cortisol
levels are intermittent or constant, because
chronic pain patients may experience high
cortisol levels, even if intermittent, over long
time periods and develop sustained
complications. It is very likely that joint
degeneration, renal stones, vertebral collapse,
hypertension, dementia, and hyperlipidemia so
commonly observed in chronic pain patients
are the results of intermittent hypercortisolemia
over an extended period of time. Of particular
concern is that hypercortisolemia causes
calcium resorption, which is the apparent
cause of osteoporosis, dental erosion, joint
degeneration, nephrolithiasis (renal stones)
and vertebral collapse. The problem of calcium
resorption in pain patients may be
compounded by poor diet, a lack of dietary
supplements, and immobilization due to pain
[29, 76, 78, 80, 81]. Pain practitioners must be
alert and recognize these complications and
evaluate patients for cortisol abnormalities.
Long-term hypocortisolemia, often known
as Addison’s Disease, has a different set of
complications. Hypocortisolemia produces
weight loss, muscle wasting, mental apathy,
hypotension, and, if not detected and treated, it
may cause sudden death. In patients who take
opioids, testosterone is the major hormone
suppressed, although opioids may also
suppress cortisol. It is not known the precise
opioid dosage or time frame necessary for
suppression of testosterone and/or cortisol to
occur. However, it is known that long-acting
opioids and a longer duration of opioid
treatment play a role [74]. The author has
observed that suppression may occur within
90 days after a patient initiates opioid use.
Adrenal insufficiency was first described by
Thomas Addison in 1855 [83]. Serum testing and
even the name cortisol were not yet conceived at
the time. Thomas Addison’s treatise was called,
‘‘On the Constitutional and Local Effect of
Disease of the Supra-Renal Capsules.’’ He
reported on 11 patients who died from severe
disease of the supra-renal capsules (now called
the adrenal glands), and who had a similar
clinical history of weight loss, muscle wasting,
lowered blood pressure, decreased mental
ability, yellowish hue to the skin, and
pigmentation around scars, gums, axillae, and
skin creases [83]. Interestingly, two of his
11 cases had severe pain. One had facial pain
and the other had extremity neuropathy. Severe,
chronic pain may cause significant cortisol
suppression, and a typical Addison’s clinical
profile will ensue (Table 4). Pain practitioners
should suspect this condition if such symptoms
as weight loss, muscle wasting, hypotension,
and brown pigmentation on the skin are
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present. Unfortunately, several conditions in
pain patients may produce a physical profile
similar to Addison’s disease. These include
immobility, inadequate diet, depression,
fatigue, sleep deprivation, malabsorption,
autoimmune phenomenon, and malignancy.
Only serum cortisol testing can reliably
distinguish adrenal insufficiency from these
other unfortunate ramifications of severe,
chronic pain. Hydrocortisone replacement in
hypocortisolemia, as well as enhanced pain
control, is essential. It can even be a simple
life-saving endeavor (see Table 4) [71, 75, 84].
SERUM TESTING
AND REPLACEMENT
Due to the two phases, stimulation and
depletion, of pain’s effect on the HPATG
system, practitioners should be prepared for
either too high or too low serum hormone
levels when they are assayed. Table 5 shows a
series of serum cortisol levels in 40 intractable
pain patients referred to the Veract Intractable
Pain Clinic. Note that some are high, some low,
and some are normal. In particular, it should be
noted that one individual had a cortisol
concentration of less than 1.0 lg/dL. This is
clearly a dangerous sign, as it indicates that the
patient’s adrenals are nearly non-functional
[81]. Death may suddenly occur in this
situation. I would regard a cortisol level of less
than 1.0 lg/dL to be a life-threatening
emergency that requires immediate hormone
replacement with hydrocortisone.
Replacement or partial replacement of
hydrocortisone, pregnenolone, DHEA, or
testosterone is rightfully emerging as a new
procedure in pain treatment [75, 81]. The
benefits appear numerous. In early reports, less
medication, particularly opioids, is required if
hormone serum levels are normal prior to their
initiation [77]. The author highly recommends
that hormone testing and necessary
replacement can be done before long-acting




Opioids, particularly those that are long-acting
or delivered by the intrathecal route, may
suppress some hormone production [66–74].
Precise opioid dosages that may produce
suppression have not been—and probably
cannot be—determined due to individual
biologic differences [60, 70]. It is the
constancy of sustained-action opioids,
however, that produces a 24-h blood and
brain concentration that does not allow the
HPATG to produce its usual, normal output of
hormones [63, 68, 69, 76]. Suppressed levels of
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Features were reported in Addison’s original 1855 [85]
description of patients who died of adrenal failure
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testosterone are the most common problem
with opioid administration, but cortisol,
pregnenolone, and DHEA may also be
suppressed [67, 70]. For reasons that are
unclear, the thyroid hormones, T3 and T4, are
seldom suppressed [25, 70]. The predilection
for testosterone suppression is believed to be
due to the tendency of opioids to preferentially
suppress GRH [72]. Testosterone suppression
with long-acting and intrathecal opioids occurs
in 75–85 % of patients [66, 70, 72, 74].
Suppression may begin in the first 90 days of
opioid administration and testosterone may
remain suppressed as long as opioids are
administered. Given this extremely high
prevalence, patients who take long-acting
opioids need to be regularly screened for
testosterone, as well as pregnenolone, DHEA,
and cortisol. Replacement of these hormones
should be done, as low serum levels of any of
these hormones may be associated with poor
pain control, including symptoms of allodynia
and hyperalgesia [84, 85]. It is known that
central sensitization and neuroinflammation
due to glial cell activation are responsible for
allodynia and hyperalgesia. Some hormones,
particularly the glucocorticoids and sex
hormones, have profound immune effects on
the CNS [39, 41, 49, 54]. Hormone
replacement has been reported to relieve
allodynia and hyperalgesia in some patients
[75, 84]. In a patient who takes opioids, a low
serum hormone concentration may be due to
opioids, pain, or both. Consequently, in
clinical practice, hormone replacement may
have to be performed without knowing
precisely which mechanism is primarily
responsible for hormone deficiencies.


















1 1.1 11 28.9 21 6.2 31 4.7
2 4.9 12 11.6 22 4.0 32 16.2
3 2.2 13 24.1 23 4.3 33 4.3
4 2.2 14 3.9 24 30.1 34 29.8
5 13.0 15 28.9 25 1.3 35 22.7
6 28.5 16 32.5 26 16.1 36 25.8
7a 0.6 17 29.0 27 18.5 37 18.7
8 4.3 18 27.3 28 9.6 38 9.0
9 3.7 19 19.2 29 3.4 39 21.8
10 5.0 20 8.6 30 10.8 40 19.8
Patients were referred, undertreated and claimed their pain to be disabling and constant. Note that levels were above and below
the normal range, indicating uncontrolled pain. Overall mean (standard deviation, SD) cortisol level among the 40 patients:
13.9 lg/dL (10.3). Mean (SD) cortisol level among those (n = 12) with high ([20 lg/dL) concentration: 27.5 lg/dL (10.8).
Mean (SD) cortisol level among those (n = 14) with low (\5 lg/dL) concentration: 3.2 lg/dL (1.4)
a Patient had such a low level that adrenal failure and death could occur without immediate hydrocortisone replacement
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CONCLUSION
The basic physiologic effect of pain on the
endocrine system is one of severe stress. Pain
initially stimulates the HPATG system to
produce and secrete extra hormones from the
adrenals, gonads, and thyroid. Hormones,
including cortisol, pregnenolone, DHEA,
testosterone, and thyroid (T3 and T4) travel
from their producing glands to distinct tissue
targets, including injured nerves and the CNS.
Hormones provide immunologic, anti-
inflammatory, and regenerative properties for
cellular protection and healing. In the
stimulation phase of severe pain, serum
hormone levels are elevated. If pain persists
unabated for too long, the hormonal system is
unable to tolerate the stress of pain, and
hormone production may be decreased
causing serum hormone levels to drop below
normal.
The most serious hormone complications of
severe chronic pain are hyper- and
hypocortisolemia. Cortisol serum levels rise
and fall with emotion, exercise, nutrition, and
disease states. Exercise is well known to
positively modify cortisol levels, and this
activity is highly recommended in pain
patients. Chronic hypercortisolemia has
numerous complications related to increased
calcium resorption and includes osteopenia,
joint degeneration, tooth decay, degenerative
arthritis, vertebral collapse, and renal stones.
Hypocortisolemia may occur in severe, under-
treated pain, and cortisol levels may drop below
1.0 lg/dL, which may be too low to sustain life.
Low serum cortisol levels are clinically
manifested by weight loss, muscle wasting,
weakness, hypotension, and pigmentation
around scars and skin creases.
Hormone serum levels serve as biomarkers for
uncontrolled pain. Before embarking on therapy
with long-acting opioids and other pain
treatment modalities that carry risks, a minimal
hormone assessment should be made to
determine whether a chronic pain patient has
normal serum levels of cortisol, pregnenolone,
DHEA, and testosterone. Early clinical experience
indicates that the use of opioids, and possibly
other pharmaceutical agents, can be minimized if
hormone homeostasis is achieved prior to
introduction of these agents. It is cautioned,
however, that the patient’s report of pain and
need for analgesic medication be paramount, and
that hormone serum levels should never be the
determinant of proper analgesia.
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